← Case Library

Clause 7.2

⚖ 278 PMCPA cases 🔒 Members see all 278 cases

What this clause covers

Claims must be based on an up-to-date evaluation of all the evidence and must not give a misleading impression. Cherry-picking favourable data, ignoring contradictory studies, or using outdated references are common routes to breach. Robust literature reviews and regular content audits are essential.

PMCPA Cases — Clause 7.2

278 cases
📅 8 Mar 2026 · Teva UK

Teva UK Ltd: Guidelines in Practice insert on switching to CFC-free beclometasone inhalers (Qvar) found misleading and promotional

Clause 7.2 Clause 7.4 Clause 9.5
📅 8 Mar 2026 · Roche Products

AUTH/2191/12/08: Roche misleading comparative and “cost-effective” claims in Bondronat hospital detail aid (Novartis complaint)

Clause 7.10 Clause 7.2 Clause 7.3 Clause 7.4 +2 more
📅 8 Mar 2026 · Merz Pharma UK

Allergan v Merz Pharma UK Ltd: Xeomin promotion claims on complexing proteins and dosing ratio

Clause 7.2
🔒

See all 278 cases for Clause 7.2

Case Library members get full access to every PMCPA ruling, searchable by clause, company, outcome, and sanction.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

Already a member? Sign in

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free